Shilliday I R, Sherif M
Renal Unit, Monklands Hospital, Monkscourt Avenue, Airdrie, UK, ML6 0JS.
Cochrane Database Syst Rev. 2004(1):CD003421. doi: 10.1002/14651858.CD003421.pub2.
The incidence of delayed graft function in cadaveric grafts has increased over the last few years due in part to the large demand for cadaveric kidneys necessitating the use of kidneys from marginal donors. Calcium channel blockers have the potential to reduce the incidence of post-transplant acute tubular necrosis (ATN) if given in the peri-operative period. However, there is controversy surrounding their use in this situation with no consensus as to their efficacy.
To evaluate the benefits and harms of using calcium channel blockers in the peri-transplant period in patients at risk of ATN following cadaveric kidney transplantation.
We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library issue 2, 2003) MEDLINE (1966 to January 2003) and EMBASE (1980 - January 2003). The Trials Search Coordinator was contacted to develop the search strategy.
Randomised controlled trials comparing calcium channel blockers given in the peri-transplant period with controls were included. Quasi-randomised trials were excluded.
Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes are reported as relative risk (RR) and measurements on continuous scales are reported as weighted mean differences (WMD) with 95% confidence intervals (CI).
Nine trials were suitable for inclusion. Treatment with calcium channel blockers in the peri-transplant period was associated with a significant decrease in the incidence of post transplant ATN (RR 0.57, 95%CI 0.40 to 0.82) and delayed graft function (RR 0.44, 95% CI 0.28 to 0.69). There was no difference between control and treatment groups in graft loss, mortality, requirement for haemodialysis. There was insufficient information to comment on adverse events.
REVIEWER'S CONCLUSIONS: These results suggest that calcium channel blockers given in the peri-operative period may reduce the incidence of ATN post-transplantation. The result should be treated with caution due to the heterogeneity of the trials which made comparison of studies and pooling of data difficult.
在过去几年中,尸体肾移植中移植肾功能延迟的发生率有所增加,部分原因是对尸体肾的大量需求使得必须使用边缘供体的肾脏。钙通道阻滞剂若在围手术期使用,有可能降低移植后急性肾小管坏死(ATN)的发生率。然而,在这种情况下其使用存在争议,对于其疗效尚无共识。
评估在尸体肾移植后有发生ATN风险的患者围移植期使用钙通道阻滞剂的益处和危害。
我们检索了Cochrane肾脏组的专业注册库、Cochrane对照试验中心注册库(CENTRAL,收录于《Cochrane图书馆》2003年第2期)、MEDLINE(1966年至2003年1月)以及EMBASE(1980年至2003年1月)。联系试验检索协调员制定检索策略。
纳入比较围移植期给予钙通道阻滞剂与对照组的随机对照试验。排除半随机试验。
由两名评价员独立提取数据并进行质量评估,分歧通过讨论解决。二分法结局以相对危险度(RR)报告,连续量表测量结果以加权均数差(WMD)及95%置信区间(CI)报告。
九项试验适合纳入。围移植期使用钙通道阻滞剂治疗与移植后ATN的发生率显著降低(RR 0.57,95%CI 0.40至0.82)以及移植肾功能延迟(RR 0.44,95%CI 0.28至0.69)相关。对照组和治疗组在移植肾丢失、死亡率、血液透析需求方面无差异。关于不良事件的信息不足,无法进行评论。
这些结果表明围手术期给予钙通道阻滞剂可能降低移植后ATN的发生率。由于试验的异质性使得研究比较和数据合并困难,该结果应谨慎对待。